NEW YORK (360Dx) – Israeli in vitro diagnostics firm Todos Medical today announced a distribution deal with Orot+ for Todos' TM-B2 blood tests for breast cancer screening in Romania and Austria.
Orto+, headquartered in Tel Aviv, Israel will be responsible for the costs of marketing and distributing TM-B2. Todos will use data from the commercialization efforts to support further development and commercialization of the test in other geographies, it said. Additional terms of the agreement were not disclosed.
Rehovot-based Todos' tests leverage the firm's TBIA method for cancer screening using peripheral blood analysis, which is based on the effect of cancer on a patient's immune system. The technology combines biochemistry, physics, and signal processing. Todos' TM-B1 and TM-B2 tests are CE marked.